로그인
회원가입
Korean
Korean
English
Chinese
Japanese
Home
Introduction
Contact us
People
PI
Members
Research
Projects
Lab Facility
Publications
Papers
Books
Patents
Photo gallery
Photo gallery
Board
Projet update
Recruiting
Journal club
Home
People
Research
Publications
Photo gallery
Board
Home
Introduction
Contact us
People
PI
Members
Research
Projects
Lab Facility
Publications
Papers
Books
Patents
Photo gallery
Photo gallery
Board
Projet update
Recruiting
Journal club
MOON LAB SNS 바로가기
트위터
페이스북
네이버블로그
MOON LAB
홈페이지 바로가기
MOON LAB
Moon lab pursues development of novel therapeutics for breast, ovary, and prostate cancer
Journal club 글답변
이름
필수
비밀번호
필수
분류
선택하세요
Journal Club
Projet update
HTML
제목
필수
웹에디터 시작
> > > Date: 2021.03.30 > > ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2 ovarian cancer cells > > Mol Cancer Thr 2020; 19: 199-210. > > Abstract > Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved to treat recurrent ovarian cancer with BRCA1 or BRCA2 mutations, and as maintenance therapy for recurrent platinum-sensitive ovarian cancer (BRCA wild-type or mutated) after treatment with platinum. However, the acquired resistance against PARPi remains a clinical hurdle. Here, we demonstrated that PARP inhibitor (olaparib)–resistant epithelial ovarian cancer (EOC) cells exhibited an elevated aldehyde dehydrogenase (ALDH) activity, mainly contributed by increased expression of ALDH1A1 due to olaparib-induced expression of BRD4, a member of bromodomain and extraterminal (BET) family protein. We also revealed that ALDH1A1 enhanced microhomology-mediated end joining (MMEJ) activity in EOC cells with inactivated BRCA2, a key protein that promotes homologous recombination (HR) by using an intrachromosomal MMEJ reporter. Moreover, NCT-501, an ALDH1A1-selective inhibitor, can synergize with olaparib in killing EOC cells carrying BRCA2 mutation in both in vitro cell culture and the in vivo xenograft animal model. Given that MMEJ activity has been reported to be responsible for PARPi resistance in HR-deficient cells, we conclude that ALDH1A1 contributes to the resistance to PARP inhibitors via enhancing MMEJ in BRCA2−/− ovarian cancer cells. Our findings provide a novel mechanism underlying PARPi resistance in BRCA2-mutated EOC cells and suggest that inhibition of ALDH1A1 could be exploited for preventing and overcoming PARPi resistance in EOC patients carrying BRCA2 mutation. > >
웹 에디터 끝
첨부파일
파일추가
파일삭제
자동등록방지
숫자음성듣기
새로고침
자동등록방지 숫자를 순서대로 입력하세요.
작성완료
취소
전화걸기
문자상담
PL
MEMBERS